EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
15/09/2025
Voltar para busca
Dado oficial do USPTO
ULTRAGENYX
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Snapshot rápido
ST13
US500000097980518Classe
1, 5, 16, 36, 41, 42, 44
Pedido
97980518
Registro
7907676
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
37
Atualização mais recente
16/09/2025
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
1, 5, 16, 36, 41, 42, 44
Data de depósito
21/12/2022
Data de registro
19/08/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
19/08/2025
Última transação
16/09/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
2017-11-00
Primeiro uso no comércio
2017-11-00
Código do desenho
5
Tipo de titular
03
Localização do titular
Novato, CA
Examinador
HELLMAN, ELI
Unidade examinadora
L20
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the word "ultragenyx" in a lower-case stylized font.
Titulares e representantes
Titulares
Ultragenyx Pharmaceutical Inc.
Representantes
Brian Focarino Cooley LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 16Classe 36Classe 41Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicalbiologicalbiochemical preparations for use in gene delivery technologynucleic acidsincludingcoding and non-coding deoxyribonucleic acidsplasmidsvectorspromotorsenhancers and other regulatory sequencesfor use in vitro laboratory use; chemicalbiologicalbiochemical preparations for use in the manufacture of pharmaceutical preparations
Classe 5
Pharmaceutical preparations for the treatment of liverhepatologicalcardiovascularcentral nervous systeminflammatoryautoimmunemusculoskeletalophthalmologicrespiratoryosteopathiconcologicendocrineorthopedicmetaboliclipid-relatedgeneticneuromuscularautosomallysosomal storageenzymehematologic and long-chain fatty acid oxidation disorders (LC-FAOD) diseases and disorders; chemicalbiologicalbiochemical preparations for use in gene delivery technology for medical usenucleic acidsincluding coding and non-coding deoxyribonucleic acidsplasmidsvectorspromotorsenhancers and other regulatory sequencesfor use in in vivo therapeutic use in gene therapy
Classe 16
Printed publicationsbooksbrochuresinformational pamphletsinformational cardsadvertisements being signs and boards of paper in the field of rare diseases and disorders
Classe 36
Financial and insurance consultation servicespatient advisorysupport and consultancy services regarding patient financesinsurance and access to medical treatment; providing financial and insurance informationproviding information and guidance in connection with health insurance benefit plans and other patient financial assistance resources; financial and insurance consultation servicesinsurance and medical and pharmaceutical access consultation servicesassisting patients and their caregivers to identify the scope of coverage offered by patient medical and pharmaceutical insurance and to identify other financial assistance resources for payment of patient treatment; insurance consultation servicesassisting patients and their caregivers to obtain authorization and payment for medical and pharmaceutical costs
Classe 41
Education and training servicesseminarsproviding non-downloadable webinarsworkshops for healthcare professionalscaregiverspatientsproviders in the field of rare diseases and disorders; online journalsblogs featuring information on rare diseases and disorders
Classe 42
Pharmaceuticalscientificmedical research and development in the field of gene therapy manufacturing technology; biomedical and scientific research in the fields of genome editinggene editinggenome engineeringgene modulationgenetic diseasesgene therapycell therapy; biomedical research in the field of gene therapy design and delivery; gene therapy design and delivery development of biochemical assays; product development in the fields of genetic therapies and effectors to regulatemodulatecharacterize disease states; pharmaceutical research and development in the field of gene therapy; scientific research in the nature of conducting clinical trials for others in the field of gene therapy design and delivery; scientific and medical researchcompiling and sharing of patient data for research purposes in the field of rare diseases and disorders; medical and scientific research information in the field of rare diseases and disorders; computer servicescreating an on-line community for registered users to obtain feedback from their peersinteract with research datashare data in the field of rare diseases and disorders; pharmaceutical research servicesrecruitment of rare disease patients for panels such as pharmaceutical research panels; providing medical research and scientific research information in the field of hypophosphatemia
Classe 44
Providing medical servicesgene therapy design and delivery services being gene therapy medical services in the field of liverhepatologicalcardiovascularcentral nervous systemendocrineinflammatorymetabolicautoimmunemusculoskeletalneurologicalophthalmologicrespiratoryhematologic diseases and disorders; medical consulting services in the field of rare diseases and disorders; healthcare servicesproviding an online database of medical and healthcare information in the field of rare diseases and disorderscollecting data and information on rare diseases and disorders for screeningdiagnosis and treatment purposes; medical information services in the nature of providing a database in the field of hypophosphatemia information based on collected patient data and information all for treatment and diagnostic purposes
Publicações
Histórico de despachos e eventos da marca no USPTO.
37 publicações encontradas
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
19/08/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
19/08/2025
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
31/07/2025
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
31/07/2025
SUPC
STATEMENT OF USE PROCESSING COMPLETE
29/07/2025
DPCC
DIVISIONAL PROCESSING COMPLETE
29/07/2025
EX2G
SOU EXTENSION 2 GRANTED
29/07/2025
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
24/07/2025
IUAF
USE AMENDMENT FILED
16/01/2025
DRRR
DIVISIONAL REQUEST RECEIVED
16/01/2025
EXT2
SOU EXTENSION 2 FILED
16/01/2025
EISU
TEAS STATEMENT OF USE RECEIVED
16/01/2025
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
16/01/2025
EEXT
SOU TEAS EXTENSION RECEIVED
16/01/2025
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
02/08/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/08/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/08/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/08/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
02/08/2024
EX1G
SOU EXTENSION 1 GRANTED
02/08/2024
EXT1
SOU EXTENSION 1 FILED
02/08/2024
EEXT
SOU TEAS EXTENSION RECEIVED
02/08/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
06/02/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/12/2023
PUBO
PUBLISHED FOR OPPOSITION
12/12/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
22/11/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/11/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/11/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/11/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/11/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
25/09/2023
GNRT
NON-FINAL ACTION E-MAILED
25/09/2023
CNRT
NON-FINAL ACTION WRITTEN
25/09/2023
DOCK
ASSIGNED TO EXAMINER
21/09/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
18/01/2023
NWAP
NEW APPLICATION ENTERED
24/12/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ULTRAGENYX ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.